UBC9

PF3D7_0915100 (UBC9) is the P. falciparum SUMO E2-conjugating enzyme of the parasite sumoylation pathway, acting together with the parasite SUMO E1-activating enzyme to recognize and transfer SUMO to substrate proteins, as demonstrated by in vitro sumoylation of RanGAP1 (PMID:23943616). A defining feature of the parasite enzyme is organism-specific selectivity at protein-protein interfaces: P. falciparum UBC9 fails to interact functionally with the human E1 enzyme, and structure-guided modeling and mutagenesis localized this specificity to divergent surface residues at the E1-E2 interface (PMID:23943616, PMID:26697886). Critical residues at the UBC9 N-terminus similarly govern its interaction with SUMO1, and substituting these for the corresponding human Ubc9 residues restored electrostatic, π-π, and hydrophobic contacts and enabled efficient cross-species SUMO-UBC9 binding, establishing these surface-accessible residues as specificity nodes and candidate parasite-selective inhibitor sites (PMID:35331687). Beyond its role as the E2 enzyme and the mapping of its interaction interfaces, the parasite substrate repertoire and cellular functions of PF3D7_0915100 have not been characterized in the available corpus.

1. 2013 High

   Establishing whether P. falciparum encodes a functional SUMO E2 enzyme and whether it could engage host machinery answered a basic question about the parasite sumoylation pathway and its druggability.

   Evidence in vitro sumoylation and binding assays with structural analysis and mutagenesis, using P. falciparum E1, UBC9, and RanGAP1 substrate

   PMID:23943616

   Open questions at the time

   • Full parasite substrate repertoire beyond RanGAP1 not defined
   • No in vivo demonstration of UBC9 function in the parasite
   • Structural basis of E1-E2 selectivity not yet resolved at atomic level
2. 2015 High

   Defining the E1-E2 interface at structural resolution answered why the parasite and human enzymes do not cross-react and pinpointed exploitable divergent residues.

   Evidence X-ray crystallography of human SUMO E1 UFD-Ubc9 complex, guiding in silico modeling, mutagenesis, and in vitro biochemistry of P. falciparum SUMO E1 and UBC9

   PMID:26697886

   Open questions at the time

   • Interface residues mapped by modeling rather than a parasite-specific crystal structure
   • Inhibitor selectivity claim not experimentally validated with actual compounds
3. 2022 Medium

   Identifying the N-terminal residues that weaken UBC9-SUMO1 binding answered which specific surface nodes drive species-specificity and confirmed they are engineerable.

   Evidence biochemical and biophysical binding assays with site-directed mutagenesis converting P. falciparum UBC9 residues to human equivalents

   PMID:35331687

   Open questions at the time

   • Single lab, single study without independent confirmation
   • Consequences of these residues for downstream substrate modification in vivo untested
4. 2020 Low

   Resistance selection against a benzoxaborole implicated the sumoylation cascade in drug response, but the evidence points to the SUMO-activating enzyme upstream rather than UBC9 itself.

   Evidence in vitro resistance selection, whole-genome sequencing, and mutation reintroduction with IC50 measurement in P. falciparum

   PMID:31992618

   Open questions at the time

   • Does not directly interrogate UBC9/PF3D7_0915100
   • Mechanistic link between sumoylation pathway and drug action unresolved

• The full parasite substrate set, in-cell function across the life cycle, and validated parasite-selective inhibition of PF3D7_0915100 remain unestablished.
• No genetic characterization of UBC9 in P. falciparum stages
• No parasite substrate atlas beyond RanGAP1
• No confirmed inhibitor exploiting the divergent interface